【24h】

p Arrhythmias in Pregnancy

机译:在怀孕p心律失常

获取原文
获取原文并翻译 | 示例
           

摘要

Increasing maternal mortality and incidence of arrhythmias in pregnancy have been noted over the past 2 decades in the United States. Pregnancy is associated with a greater risk of arrhythmias, and patients with a history of arrhythmias are at significant risk of arrhythmia recurrence during pregnancy. The incidence of atrial fibrillation in pregnancy is rising. This review discusses the management of tachyarrhythmias and bradyarrhythmias in pregnancy, including management of cardiac arrest. Management of fetal arrhythmias are also reviewed. For patients without structural heart disease, bblocker therapy, especially propranolol and metoprolol, and antiarrhythmic drugs, such as flecainide and sotalol, can be safely used to treat tachyarrhythmias. As a last resort, catheter ablation with minimal fluoroscopy can be performed. Device implantation can be safely performed with minimal fluoroscopy and under echocardiographic or ultrasound guidance in patients with clear indications for devices during pregnancy. Because of rising maternal mortality in the United States, which is partly driven by increasing maternal age and comorbidities, a multidisciplinary and/or integrative approach to arrhythmia management from the prepartum to the postpartum period is needed. (J Am Coll Cardiol EP 2022;8:120-135) (c) 2022 by the American College of Cardiology Foundation.
机译:增加产妇死亡率和发病率在怀孕已经指出心律失常过去2年在美国。与心律失常的风险更大,和患者心律失常的历史期间心律失常复发的重要风险怀孕。在怀孕正在上升。快速性心律失常和管理在怀孕bradyarrhythmias,包括心脏骤停的管理。心律失常也进行了综述。没有结构性心脏病,bblocker治疗,尤其是普萘洛尔、美托洛尔和抗心律失常的药物,如氟卡尼和心得怡,可以安全地用于治疗快速性心律失常。以最小的透视可以消融执行。以最小的透视和执行超声心动图或超声检查指导明确的适应症的患者进行设备在怀孕期间。死亡率在美国,这是部分通过增加母亲的年龄和驱动多学科和/或并发症综合心律失常管理方法从prepartum产后需要的。2022年美国心脏病学院的基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号